A trial to study infection reduction potential of Pegfilgrastim medicine in aplastic anemia patients
Not Applicable
- Conditions
- Health Condition 1: D613- Idiopathic aplastic anemia
- Registration Number
- CTRI/2023/11/059955
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
BONE MARROW PROVEN DIAGNOSIS OF APLASTIC ANEMIA
Exclusion Criteria
1.Patients who have received ATG elsewhere
2.Patients with inherited bone marrow syndromes .
3.Patients with Hepatitis B or Hepatitis C
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence of febrile neutropenia (measured by ANC count) in peg filgastrim group v/s control group.Timepoint: ABSOLUTE NEUTROPHIL COUNT WILL BE MEASURED AT BASELINE (0)AT THE TIME OF ADMISSION, AT 1 WEEK, 4 WEEKS, 12 WEEKS
- Secondary Outcome Measures
Name Time Method TO ASSESS RESPONSETimepoint: 1,3, 6 MONTHS